Table 1.
Summary of study designs, participants and outcome measures
| Shimoda et al. 1998 [19] | Kajimoto et al. 2000 [28] | Jayawardena et al. 2005 [29] | Shivaprasad et al. 2013 [30] | Ofner et al. 2013 [31] | |
|---|---|---|---|---|---|
| Study design | Single point Sucrose tolerance test | Placebo controlled cross-over trial | Double blind randomized placebo controlled cross-over trial | Double blind randomized placebo controlled trial | Randomized open label study |
| Study duration | Single point intervention | 6 weeks | 3 months | 6 weeks | 4 weeks |
| Study population | Healthy Adults | Type 2 diabetes patients | Type 2 diabetes patients | Prediabetes (IFG & IGT) | Healthy adults |
| Number of participants | 7 | 20 | 51 | 29 | 40 |
| Source of SRE | Stem | Stem | Patented product | Leaves Root bark | Root powder (Exadipin) |
| Dose of SRE | 200 mg (single dose) | 240 mg/day | Not mentioned | 500 mg/day | 600 mg/day |
| Background oral hypoglycaemic therapy | None | None | Metformin Glibemclamide | None | None |
| End point(s) | Postprandial glucose value | FBS HbA1C BMI | HbA1C | 1. FBS | |
| 2. Improvement in LDL-C |